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Abstract
Background: Radiotherapy is one of the mainstays in the treatment for cancer, but its success can be limited due
to inherent or acquired resistance. Mechanisms underlying radioresistance in various cancers are poorly understood
and available radiosensitizers have shown only modest clinical benefit. There is thus a need to identify new targets and
drugs for more effective sensitization of cancer cells to irradiation. Compound and RNA interference high-throughput
screening technologies allow comprehensive enterprises to identify new agents and targets for radiosensitization.
However, the gold standard assay to investigate radiosensitivity of cancer cells in vitro, the colony formation assay
(CFA), is unsuitable for high-throughput screening.
Methods: We developed a new high-throughput screening method for determining radiation susceptibility. Fast and
uniform irradiation of batches up to 30 microplates was achieved using a Perspex container and a clinically employed
linear accelerator. The readout was done by automated counting of fluorescently stained nuclei using the Acumen eX3
laser scanning cytometer. Assay performance was compared to that of the CFA and the CellTiter-Blue homogeneous
uniform-well cell viability assay. The assay was validated in a whole-genome siRNA library screening setting using PC-3
prostate cancer cells.
Results: On 4 different cancer cell lines, the automated cell counting assay produced radiation dose response curves
that followed a linear-quadratic equation and that exhibited a better correlation to the results of the CFA than did the
cell viability assay. Moreover, the cell counting assay could be used to detect radiosensitization by silencing DNA-PKcs
or by adding caffeine. In a high-throughput screening setting, using 4 Gy irradiated and control PC-3 cells, the effects
of DNA-PKcs siRNA and non-targeting control siRNA could be clearly discriminated.
Conclusions: We developed a simple assay for radiation susceptibility that can be used for high-throughput screening.
This will aid the identification of molecular targets for radiosensitization, thereby contributing to improving the efficacy
of radiotherapy.
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Background
Radiotherapy (RT) is one of the most commonly used
treatments for cancer. Approximately 50% of all cancer
patients are treated with RT. For many indications,
radiotherapy is combined with other treatment modalities,
such as surgery and/or chemotherapy [1-4]. The biological
basis for the therapeutic effects of RT is that the applied
ionizing radiation (IR) causes lethal double-strand breaks
in the cellular DNA leading to tumor cell death. However,
IR-induced DNA damage also triggers DNA damage
response (DDR) signaling pathways in cells. These can
result either in cell cycle arrest and DNA damage repair
or in cell death. Differences in the functioning of these
processes in different cells or under different conditions
determine the final effect of a certain dose of IR [5].
Cancer cells are generally more vulnerable to DNA damage
than healthy cells [6].
Despite its broad use and implementation of improved
methods, clinical success of radiotherapy is variable.
While survival rates after RT are high for some cancers,
for many other cancers they are not [7]. There is thus a
medical need to augment the efficacy of RT. The causes of
irradiation treatment failure are pleiotropic and include
tumor hypoxia and intrinsic resistance of cancer cells to
IR [8,9]. The mechanisms underlying radioresistance of
cancer cells are incompletely understood. At present only
a handful of genes have been described to play a role in
the radiation response. These include genes involved in
cell cycle checkpoint activation and DNA repair, such as e.g.
ATM and DNA-PKcs [10,11]. On the basis of this
knowledge, radiosensitizing drugs have been developed,
including e.g. inhibitors of EGFR pathway members,
farnesyltransferase, VEGF, ATM, DNA-PKcs and PARP
[12-14]. Another example is caffeine that targets the DDR
signaling pathway in ways that are incompletely
understood. Reported activities of caffeine include inhib-
ition of ATM-ATR kinase activity, cell cycle checkpoints
and DNA repair by homologous recombination, but other
effects are not excluded [15]. Although many of these
inhibitors proved effective radiosensitizers in preclinical
studies, up to date clinical studies showed only mod-
est results [16,17]. Also widely used chemotherapeutic
drugs were found to cooperate with IR, resulting in
increased killing of cancer cells. Radiosensitizing che-
motherapeutic drugs include cisplatin, 5-FU, gemcitabine
and temozolomide [18-21]. Many clinical trials have
been performed combining RT with chemotherapy.
Meta-analyses showed that combination treatment is
associated with significant clinical benefit, but also
increased toxicity to healthy tissue [19]. Further
improvement of clinical efficacy is often not possible
by increasing the dose of IR or of the sensitizing agent,
because normal tissue damage is already considerable.
Hence, there is a clear need to identify new targets and
drugs for more specific sensitization of cancer cells to
irradiation.
The emergence of high-throughput screening (HTS)
and of RNA interference (RNAi) technologies now allow
identification of novel candidate drugs by phenotypic
screening and new molecular targets by loss-of-function
genetic screening. However, technical obstacles with
respect to radiation response readout assays impede
comprehensive screening enterprises. The colony forma-
tion assay (CFA) is the method of choice to investigate
radiation response of cancer cells in vitro. The CFA is a
cell survival assay that tests the ability of a single cell to
grow into a colony after treatment. The CFA detects the
cytotoxic effect of a treatment, regardless of the cell
death mechanism, as long as the agent affects the cell’s
ability to produce progeny. Unfortunately, the scale of
the assay makes the CFA unsuitable for HTS. Therefore,
we set out to develop a new method to identify radiation
susceptibility genes in RNAi HTS. The readout is done by
counting fluorescently stained nuclei using the Acumen
eX3 laser scanning cytometer. As shown herein, assay
performance was similar to that of the CFA. Most
importantly, increased sensitivity to IR upon siRNA-
mediated silencing of the DDR gene DNA-PKcs could
be detected with good assay metrics in an HTS setting
and candidate radiation susceptibility genes could be
identified.
Methods
Cell culture
PC-3 and DU145 prostate cancer cell lines were main-
tained in RPMI1640 medium (Lonza, Verviers, Belgium).
A549 lung adenocarcinoma and U2OS osteosarcoma cell
lines were maintained in DMEM medium (PAA,
Cölbe, Germany). All cultures were supplemented with
10% fetal calf serum (Greiner Bio-One, Alphen a/d Rijn,
The Netherlands) and 50U/ml penicillin and 50U/ml
streptomycin (PAA, Pasching, Austria) and maintained at
37°C and 5% CO2 in a humidified atmosphere.
Construction of PC-3 cells with stable knockdown of
PRKDC
Stable knockdown cells were made using lentiviral vectors
expressing shRNA from the TRC library (Thermo Scientific
Open Biosystems). Lentiviral vectors were made by
transfection of HEK-293T cells with psPAX2 and
pMD2.G packaging constructs (Addgene, Cambridge, MA)
together with lentiviral vector clone TRCN0000006256
carrying the PRKDC-silencing shRNA sequence 5′-
CCGG-CCGGTAAAGATCCTAATTCTA-CTCGAG-TAG
AATTAGGATCTTTACCGG-TTTTT-3′; or negative con-
trol pLKO.1 Empty Vector (Cat. No. RHS4080), using
FuGENE®6 (Promega Benelux, Leiden, The Netherlands)
transfection reagent. Culture medium containing virus
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particles was harvested 2 and 3 days after transfection.
Cleared supernatant was used to transduce PC-3 cells
in the presence of 8 μg/ml polybrene (Sigma Aldrich
Chemie BV, Zwijndrecht, The Netherlands). Transduced
cells were selected using incubation in 5 μg/ml puro-
mycin (Gibco® by Life TechnologiesTM, Bleiswijk, The
Netherlands).
High-throughput irradiation method
Cells were irradiated with the indicated dose IR at a dose
rate of 6 Gy/minute using a Clinac 2300CD or TrueBeam
linear accelerator (Varian Medical Systems, Palo Alto,
CA). Microtiter plates (Greiner Bio-One) were placed in a
for this purpose specifically designed Perspex (PMMA, i.e.
near-water equivalent material in radiotherapy) container.
The overall size of the container is 58.6 x 57 x 8.3 cm with
a side wall thickness of 9.6 cm and a top and bottom wall
of approximately 2.2 cm. The container allows to irradiate
at maximum 30 ANSI/SLAS-standard culture plates
simultaneously, divided into 3 groups of 10 plates each.
Per group, the plates were clustered and stacked in 2
layers. Between groups, 2 cm thick easily removable
Perspex rods were situated. Unused plate positions
were filled with Perspex blocks. Together with the
thick container walls and the removable Perspex
rods between the groups, these blocks assure a full-
phantom photon scatter condition for all cells. This
is a requirement for a correct and reproducible dose
delivery to all cells irrespective of their position in
the container. Irradiation planning for homogeneous
dose distribution was performed as described in the
results section.
Colony formation assay
Cells were seeded in 6-well plates at a density depending
on the irradiation dose, i.e., 250 cells/well for 0–3 Gy
and 500 cells/well for 4–8 Gy; and irradiated within
16–20 hours after seeding. Seven to 10 days after irradiation,
cells were washed with PBS, fixed with 4% formaldehyde
and stained using Giemsa (Sigma Aldrich Chemie BV,
Zwijndrecht, The Netherlands) at 1:20 dilution in PBS.
Colonies containing 50 or more cells were counted.
Data shown are means from three independent experiments
done in duplicate. Survival fractions were calculated
using the formula: SF = (nr colonies/nr of cells plated)
irradiated/(nr colonies/nr of cells plated) untreated.
Data were fitted with the linear quadratic model: S =
exp(−αD-βD2), where S is the surviving fraction and
D is the IR dose.
CellTiter-Blue cell viability assay
Cells were seeded 500 cells/well in 100 μl medium and
irradiated in 96-well plates as described above. Five days
after irradiation, 20 μl CellTiter-Blue (CTB) reagent
(Promega Benelux, Leiden, The Netherlands) was added
to each well and the cells were cultured for 2 hours. Cell
viability was determined by measuring fluorescence at
540 nm excitation and 590 nm emission wavelengths
using a Tecan Infinite F200 microplate reader. Data
shown are means from three independent experiments
done in triplicate. Data were fitted using the linear
quadratic model.
Automated cell counting assay
Cells were seeded at the indicated number per well in
96-well plates. Where indicated, caffeine (Sigma-Aldrich)
was added at 2 mM final concentration 1 hour before
irradiation and cells were irradiated as described above. Five
days after irradiation, the culture medium was removed
and cells were washed with PBS and fixed with 7% formal-
dehyde for 30–60 minutes. After a second wash with PBS,
cells were optionally stored at RT until analysis. Prior to
analysis on an Acumen eX3 (TTP LabTech, Melbourne,
UK) microplate cytometer integrated with a Twister II ro-
botic system (Caliper, Teralfene, Belgium) for unattended
high-throughput data acquisition, cells were stained with
0.3 μg/well Hoechst 33342 (Sigma Aldrich Chemie
BV, Zwijndrecht, The Netherlands) in PBS for at least
30 minutes. The plates were scanned in Cytometry
Mode using a scan resolution of 1x4 μm and a laser
power of 6 mV, with a 405 nm excitation laser and a
photomultiplier tube detector equipped with 500–530 nm
detection filters. Identified fluorescent objects were used
to calculate cell numbers using the Acumen eX3 soft-
ware and user-defined parameters. These can be opti-
mized for each individual cell line. Here, we used a
single algorithm for all four cell lines included in the
study. For three of these cell lines we observed that
when cells grew to high density, adjacent nuclei were
sometimes recognized as one object. Inspection of
these objects revealed that they consisted of on average 3
nuclei. Therefore, single cell objects and cluster objects
representing 3 cells were defined separately as follows.
Small objects with a width and depth of 5–50 μm were
defined as single cells and larger objects with a width
and depth of 50–250 μm were defined as clusters of
on average 3 cells. The cell number was calculated by
the sum of the number of small objects plus 3-times
the number of larger objects. Upon irradiation, a small
proportion of nuclei were enlarged and had increased
fluorescence intensity, i.e., increased DNA content. Due to
their enlarged size, these nuclei typically representing
polyploid cells were categorized among the cluster objects.
Consequently, the cell count at high IR dose was slightly
overestimated. This had, however, minimal effect on
the dose–response curves and was therefore deemed
acceptable. Data were fitted using the linear quadratic
model.
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High-throughput siRNA library screening
Whole human genome siRNA library screens for molecular
radiosensitization targets in PC-3 cells were performed
using the Thermo Fisher Scientific Dharmacon siARRAY
library. PC-3 cells were seeded 1,500 cells per well in
96-well microtiter plates. The next day, they were
transfected with 20nM siRNA using 0.02% DharmaFECT1
(Thermo Fisher Scientific Dharmacon, Lafayette, CO)
transfection reagent. Two arrayed screens were done, each
comprising a total of 544 96-well plates, which were run
in two separate sessions of 272 plates each, comprising a
set of 136 plates in duplicate. One set of replicates was
irradiated with 4Gy two days after siRNA transfection; the
other set was not. To allow assay quality assessment, on
each plate two wells with a non-targeting siRNA control
(siNT#2, Cat. No. D-001206-14-20) and two wells with
PRKDC siRNA (Cat. No. M-005030-01-0020) as positive
control were included. Thus, four screening sessions were
done, each including 272 irradiated positive controls, 272
irradiated negative controls, 272 non-irradiated positive
controls and 272 non-irradiated negative controls. The
counted cell numbers were corrected for plate, session
and screen effects by means of a linear regression model
fitted to the log-2 intensities of the entire experiment
simultaneously. This normalization ensures estimation of
technical effects is robust, since estimates are unlikely to
be affected by deviations observed on a few wells, or for
only one replicate. In addition, it preserves the irradiation
effect, as each technical factor corrected for always
involves both irradiated and non-irradiated observations.
In order to find siRNAs that yielded a significantly larger
difference in cell viability before and after irradiation,
compared to the difference in cell viability measured for
negative controls, a linear regression model with treatment
effect was fitted to the normalized data, and this treatment
effect was compared between each siRNA and all negative
controls (i.e. 1,088 with IR and 1,088 without IR). The
regression model thus includes main effects for treatment
and for siRNA type (negative control or the siRNA
chosen), as well as an interaction effect between treatment
and siRNA that is used to test for siRNAs with different
treatment effect, compared with controls. As the model is
fitted for each siRNA, a list of t-statistics for the interaction
effects, and corresponding p-values corrected for multiple
testing by controlling the false discovery rate (FDR),
is produced. Those siRNAs that are associated with
significantly less cell survival in combination with IR
are considered radio-sensitizers.
Results and discussion
High-throughput irradiation
The primary objective of this study was to develop a
method that could be used to measure IR-induced
effects on cell viability in an HTS setting. Therefore,
we first designed a high-throughput method for
uniform irradiation of cell cultures. For this, we
employed a clinically used linear accelerator with
15MV beam and a specially designed Perspex box
capable of containing a variable number of up to 30
cell culture plates (Figure 1a). Any open positions in
the box were filled with Perspex blocks, ensuring a
full-phantom photon scatter condition and thus a
correct and reproducible dose delivery to all cells irre-
spective of their position in the container. Several
irradiation regimes were investigated, aiming at homo-
geneous irradiation of variable amounts of cell culture
b)a)
Figure 1 High-throughput irradiation method. a) Clinac 2300CD linear accelerator with the container specifically designed for HTS
experiments in place; (b) CT-scan image of the container used for irradiation dose calculation and planning. The image was taken after 10Gy
irradiation. The green cross represents the isocenter used during this phantom dose calculation. The red dot indicates the position receiving the
highest dose. The black, green and purple lines indicate the 100%, 95% and 90% isodose, respectively. The distance from the gentry to the
container (SSD) is 141 cm.
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a) b)
d)c)
Figure 2 Comparison of three different cell viability assays. Surviving fractions of PC-3 (a), DU145 (b), A549 (c) and U2OS (d) cells upon
0–8 Gy IR, as measured by CFA (open circles), CellTiter-Blue assay (closed circles) or Acumen automated cell counting (triangles). In CellTiter-Blue
and Acumen assays, 500 cells were seeded per well. Data points are means from three independent experiments. Graphs were drawn after fitting
the data to the linear quadratic equation. The α and β values calculated with this equation and correlation coefficients are given in Table 1.
Table 1 The table lists α and β linear quadratic model values and the correlation coefficient calculated in Figure 2
Cell
line
CFA Acumen CTB
α β R2 α β R2 α B R2
PC-3 0.06 ± 0.02 0.08 ± 0.01 0.99 0.07 ± 0.04 0.04 ± 0.01 0.99 0.004 ± 0.02 0.03 ± 0.003 0.99
DU145 0.22 ± 0.02 0.05 ± 0.01 0.99 −0.01 ± 0.04 0.08 ± 0.01 0.99 −0.22 ± 0.04 0.07 ± 0.09 0.97
A549 0.12 ± 0.02 0.04 ± 0.01 0.99 0.09 ± 0.03 0.04 ± 0.01 0.99 −0.03 ± 0.03 0.02 ± 0.01 0.98
U2OS −0.01 ± 0.02 0.14 ± 0.01 0.99 −0.01 ± 0.09 0.11 ± 0.04 0.97 −0.01 ± 0.06 0.02 ± 0.01 0.85
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plates. For each regime, the dose distribution over the
cells and the irradiation time, expressed in Gy/monitor
unit, was calculated. Hereto, a CT scan of the
container, with the maximum number of plates in it,
was made (Figure 1b). This scan was used as input for
treatment planning using Varian Eclipse treatment
planning technology and the AA-Algorithm. This
procedure is similar as used in modern daily dose
calculation for individual patient radiotherapy treat-
ment. A regime was accepted if the dose varied less
than 5% over all positions, which variation is not detect-
able in radiobiological cell-responses. This resulted in three
different irradiation regimes, for up to 3 plates in a single
layer; 4–6 plates in two layers; and 30 plates in two layers,
respectively. In each regime, the absolute dose in Gy desired
to be delivered to the cells could be obtained by
adjusting the number of monitor units, i.e., the treat-
ment time. Irradiation of a set of plates at each tested
dose up to 8Gy was always completed within 1 minute,
allowing irradiation of genome-wide screens in 96-well
culture plates within 1 hour including time to replace
batches. This provides a strict treatment schedule for
the entire screen and allows using the irradiation
source for screening experiments during breaks in the
daily clinical routine.
Comparison of IR dose-responses measured using three
different cell viability readout methods
Four different human cancer cell lines, i.e., PC-3 and
DU145 prostate cancer cells, U2OS osteosarcoma cells
and A549 lung adenocarcinoma cells, were seeded in cell
culture plates and subjected to 0–8 Gy IR 16-20 h later.
Next, they were subjected to cell viability analysis using
three different assays, i.e., the CFA in which colonies were
fixed and counted 8–10 days after IR; the CellTiter-Blue
(CTB) assay that is based on the ability of living cells to
convert a redox dye into a fluorescent end product; and a
newly developed method in which cells are allowed to
proliferate for 5 days and are then fixed and counted by
fluorescent laser scanning of stained nuclei using the
Acumen eX3 microplate cytometer. Alternative methods
for high-throughput cell counting, such as automated
image analysis or automated microscopy, could in principle
be used as well. However, the method using the Acumen
eX3 cytometer has the advantage of very rapid whole-well
data collection with much reduced data storage capacity
requirement.
Surviving fractions were calculated relative to untreated
controls and dose–response curves were produced by
fitting the data to the linear-quadratic model (Figure 2
and Table 1). As can be seen in Figure 2, the four cell lines
y = 0.6825x + 0.4987
R2 = 0.8687
U2OS
y = 0.9431x + 0.051
R2 = 0.983
U2OS
y = 1.0342x + 0.0644
R2 = 0.969
A549
y = 1.0477x + 0.0666
R2 = 0.9583
DU145
y = 0.942x + 0.0901
R2 = 0.9971
0
0.2
0.4
0.6
0.8
1
A
cu
m
en
 S
F
CFA SF
PC-3
y = 0.8617x + 0.2582
R2 = 0.9172
A549
y = 0.8792x + 0.4323
R2 = 0.581
DU145
y = 0.7867x + 0.3022
R2 = 0.9195
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF 
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
CFA SF
0 0.2 0.4 0.6 0.8 1 1.2
C
T
B
 S
F
PC-3
Figure 3 Correlation of IR dose-responses measured by automated cell counting or CTB metabolic activity assay to the CFA. Surviving
fractions are derived from Figure 2. In each panel the SFs determined by CFA (x-axis) are plotted against the SFs determined by automated cell
counting (Acumen; y-axis upper panels) or against the SFs determined by CTB assay (y-axis lower panels) for the indicated cell lines. The regression
equation and correlation coefficient are given in each panel.
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displayed modestly different sensitivities to IR. Their
surviving fraction upon 2Gy irradiation (SF2) varied from
0.5 for DU145 cells to 0.7 for PC-3 cells, as measured by
the CFA. Importantly, Figure 2 furthermore shows that the
CFA and automated cell counting assays reported quite
similar survival data, whereas the CTB assay consistently
suggested a higher cell survival upon irradiation. The CTB
assay was thus less sensitive in detecting the effects of IR
on cell viability. Upon low dose irradiation of DU145 cells,
the CTB assay even measured increased metabolic activity.
This is consistent with an earlier observation showing
increased uptake and conversion of MTT metabolic
activity reagent upon irradiation at low to intermediate
dose [22,23]. This effect thus disqualifies cell viability assays
based on metabolic activity measurement for quantification
of IR effects on cell viability, as it could inadvertently be
interpreted as an IR-induced stimulation of cell viability
(SF2 above 1). In contrast, an assay that simply counts cells
regardless of their metabolic activity such as the method
using automated laser scanning used here is not sensitive
to this confounding effect. Figure 3 shows the comparison
of the observed SF at all tested doses using the three assays,
further illustrating that the cell counting assay data repro-
duced those of the CFA better than did the CTB assay.
Excellent correlations were observed between the CFA and
automated cell counting assays on all four cell lines (R2
ranging from 0.96 to 1), whereas the results of CFA and
CTB assays correlated only modestly (R2 ranging from 0.58
to 0.92). In particular at higher dose, and thus lower SF,
CFA and CTB values differed considerably (i.e., 26-50% as
deduced from the regression equation crossing points). In
contrast, automated cell counts and CFA values differed
only 5-9% at this point. On the basis of these observations,
we conclude that - at least for the four cell lines studied -
the Acumen automated cell counting assay reproduces
radiation responses measured in the CFA better than the
CTB assay. Therefore, we further evaluated the automated
cell counting assay for its utility in detecting IR dose-
responses in cancer cells.
We chose the PC-3 cell line for further experiments and
determined its response to IR as detected by automated cell
counting upon irradiation at different cell densities. Figure 4
shows that PC-3 cells irradiated at lower cell density pro-
duced lower survival fractions than cells seeded at higher
density. This latter condition compares very well to the
conditions in the CFA, where cells are either irradiated at
low cell density, or seeded at low density immediately upon
irradiation. PC-3 cells irradiated at higher cell density
exhibited dose response curves with smaller angles of
declination, in particular in the linear part of the
curve. Most likely, this is caused by a technical limitation
of the readout method, which might underestimate the
actual cell number at very high cell densities. Hence,
low cell densities are preferred for detection of IR
effects on PC-3 cell survival as this yields data more
approaching CFA results. Nevertheless, also at higher
cell densities the effect of irradiation on cell survival was
measurable and dose–response data could be fitted to the
linear quadratic model reliably. Therefore, the assay
for radiation susceptibility by automated cell counting
can be used at a range of PC-3 cell densities.
Detection of radiosensitization by silencing or
pharmacological inhibition of radioresistance genes
To investigate whether the automated cell counting
assay could be used to detect radiosensitization,
PC-3.pLKO.1-shPRKDC cells were made by stably
transducing PC-3 cells with a lentiviral vector
expressing a short hairpin RNA that targets the known
radiation susceptibility gene PRKDC, encoding the
DNA-dependent protein kinase (DNA-PK) catalytic
subunit DNA-PKcs. As control, PC-3.pLKO.1-EV cells,
i.e., PC-3 cells with stable expression of an empty lenti-
viral vector, were generated. After subjecting the cells to
a dose-range IR, cell survival was measured by CFA or
by automated cell counting. As can be seen in Figure 5a
and b, radiosensitization by silencing PRKDC was
clearly detectable by both methods. Silencing PRKDC
Figure 4 The effect of cell density on the irradiation
dose–response measured by automated cell counting.
Dose-responses of PC-3 cells seeded 500 cells/well (open circles);
750 cells/well (closed circles); 1,000 cells/well (open triangles); or
1,500 cells/well (closed triangles) and irradiated 0–8 Gy. Graphs
were prepared by fitting the data to the linear quadratic model.
Correlation coefficients were above 0.98 for all graphs.
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increased mainly the α values of the linear-quadratic
equations (see Table 2), which is consistent with
inhibition of DNA repair. Although the two methods
displayed different surviving fractions upon irradi-
ation, and thus different absolute irradiation effects,
they showed quite comparable relative cell survival
due to PRKDC silencing at all IR doses tested. Hence,
the automated cell counting assay detected radiosensi-
tization as well as did the CFA.
To independently validate the utility of the automated
cell counting method to detect radiosensitization, PC-3
cells were treated with the radiosensitizing compound caf-
feine and subjected to a dose-range IR. Figure 5c and
Table 2 show that the automated cell counting assay clearly
detected radiosensitization of PC-3 cells by caffeine. Hence,
the method could be used to detect radiosensitization by
gene silencing as well as by pharmacological inhibition.
This suggests that the assay could be useful to identify new
molecular targets by genetic screening and novel candidate
drugs by chemical compound screening.
Validation of the assay in a high-throughput screening
setting
Finally, we used the high-throughput irradiation method
and automated cell counting assay to perform arrayed
whole human genome siRNA library screens for molecular
radiosensitization targets in PC-3 cells. Integration of the
Acumen eX3 cytometer into a robotic system allowed un-
supervised data collection from fixed and stained cells in
stacked plates overnight. Two screens were performed,
which were each run in two separate sessions. Each session
comprised a duplicate set of plates. One set was irradiated
with 4Gy two days after siRNA transfection; the other set
was not irradiated. Table 3 shows the experimental design
of the screen with plate numbers.
Four days after irradiation, cells were fixed and nuclei
were stained and analyzed by Acumen eX3 laser scanning.
The counted cell numbers were normalized by means of a
linear regression model. Acceptable inter-assay reproduci-
bility was observed, with Pearson correlation coefficients of
0.7 for the untreated and 0.8 for the irradiated condition,
respectively (not shown). To allow assay quality assessment,
on each assay plate two wells with non-targeting siRNA
a) b) c)
Figure 5 Detection of radiosensitization by automated cell counting. (a) PC-3.pLKO.1-EV cells (open circles) and PC-3.pLKO.1-shPRKDC cells
(closed circles) were subjected to 0–6 Gy IR and dose-responses were determined by CFA. (b) PC-3.pLKO.1-EV cells (open circles) and
PC-3.pLKO.1-shPRKDC cells (closed circles) were seeded 1,000 cells/well, subjected to 0–6 Gy IR and dose-responses were determined by
automated cell counting. (c) PC-3 cells seeded 1,000 cells/well and cultured with (closed circles) or without (open circles) caffeine were
subjected to 0–6 Gy IR and dose-responses were determined by automated cell counting. Graphs were drawn after fitting the data to
the linear quadratic equation. Data shown are means with SEM of three independent experiments. The α and β values of the equations are given
in Table 2.
Table 2 The α and β linear quadratic model values
calculated on the data shown in Figure 5
α β
a)
PC-3 pLKO.1-EV −0.023 ± 0.027 0.102 ± 0.001
PC-3 pLKO.1-shPRKDC 0.158 ± 0.058 0.142 ± 0.028
b)
PC-3 pLKO.1-EV 0.008 ± 0.039 0.065 ± 0.012
PC-3 pLKO.1-shPRKDC 0.142 ± 0.038 0.069 ± 0.013
c)
PC-3 untreated 0.135 ± 0.035 0.014 ± 0.01
PC-3 2 mM caffeine 0.415 ± 0.047 −0.026 ± 0.011
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and two wells with PRKDC siRNA were included. Figure 6a
shows box-and-whisker plots of these control siRNAs in
the two screens combined. As can be seen, IR caused a
small decrease in viability of control siRNA-transfected
cells. Silencing PRKDC alone also appeared to affect cell
viability. The strongest reduction in cell viability was
observed upon combined irradiation and PRKDC knock-
down. These data were used to determine assay quality
metrics by calculating the Z’-factor, a measure for the
magnitude of difference between the experimental groups
capturing the variability in the populations [24]. An assay
with a Z’-factor > 0 is considered to have acceptable
resolution for successful hit identification [25]. Not assum-
ing a normal distribution of the data, nonparametric statis-
tics were used to calculate robust Z’-factors (Figure 6b). As
can be seen, in all four screening sessions, robust Z’-factors
were negative for the control condition and above 0
upon irradiation. This means that while non-targeting
and PRKDC siRNA transfected cultures could not be
discriminated in terms of cell viability in the absence
of IR, reduced cell viability was reproducibly detected in
PRKDC silenced cultures after irradiation. Thus, the high-
throughput screening method allowed identification of
differences in cell viability only becoming apparent upon
irradiation and silencing of a radiation susceptibility gene.
Comparison of treatment effect between each siRNA
from the genome-wide library and all non-targeting
controls is shown in Figure 6c. siRNAs exhibiting a negative
t-statistic for the differential effect of irradiation compared
with negative controls, i.e., decreased cell survival upon
combined gene silencing and irradiation, and a low false
discovery rate (FDR) represent possible radiosensitization
targets. Hit identification was done by testing the strength
of the combined effect of each siRNA with IR against all
non-targeting siRNA controls with and without IR. This
way, we selected high-confidence molecular targets for
radiosensitization, which could subsequently be validated
with independent RNAi reagents and using the CFA
(results to be published separately). One of these candi-
dates is the known radiation susceptibility gene MAD2L2.
MAD2L2 encodes a component of the mitotic spindle as-
sembly checkpoint protein complex [26]. Knockdown of
Table 3 Experimental design of the RNAi HTS
Screen 1 2
Session 1 2 3 4
Plates 1-136 1-136 137-272 137-272 1-136 1-136 137-272 137-272
Treatment 4Gy None 4Gy None 4Gy None 4Gy None
a) b) c)
Figure 6 Detection of radiosensitization by automated cell counting in a high-throughput siRNA library screening setting.
(a) Box-and-whisker plots depicting the data of the positive and negative siRNA controls included in the screen. The whiskers indicate the 2.5th/97.5th
percentiles. Outliers are depicted by individual dots. (b) Robust Z’ factors of the four screening sessions. Each circle represents the result of one session,
with IR (closed circles) or without IR (open circles). (c) Volcano plot of the combined effect of gene silencing and IR on cell survival. The plot depicts
the interaction t-statistic and percent false discovery rate (FDR) of all siRNAs in a genome-wide siRNA screen targeting approximately 21,000 human
genes. Radiosensitizing siRNAs exhibit a negative t-statistic and low FDR. The position of siMAD2L2 (t-statistic = − 0.61; FDR = 8.9%) is indicated.
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MAD2L2 has been reported to increase chromosomal ab-
errations in response to DNA damage and to sensitize
cancer cells to DNA damaging treatments, including ir-
radiation [27,28]. Together, these results confirmed
the utility of the automated cell counting assay using a
laser scanning cytometer for identification of radiation
susceptibility genes by high-throughput screening.
Conclusions
We developed a simple high-throughput assay for identify-
ing radiation susceptibility genes. Batch-wise irradiation
was conveniently performed employing a clinically used
linear accelerator during breaks in the daily clinical routine.
Automated cell counting was done here using laser
scanning of fluorescently stained nuclei, but could if
required also be done using other methods for high-
throughput cell counting. The assay was used successfully
in a whole genome siRNA library screening campaign
identifying molecular targets for radiosensitization. This
would have been a tremendous challenge using the very
laborious CFA, which is not easily miniaturized for HTS.
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